Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Study backs Apomate for imaging heart cell death:

This article was originally published in Clinica

Executive Summary

The feasibility of using Theseus Imaging's Apomate kit to visualise cell death in heart attack patients is supported by a Dutch study published in The Lancet (July 15). Dr Leo Hofstra and colleagues from the University Hospital in Maastricht treated seven acute myocardial infarction patients with balloon angioplasty and two hours later gave them an injection of Apomate (technetium-99m-labelled annexin-V), which targets phosphatidylserine released during apoptosis. In six of the seven patients, the area of the infarct was clearly visible in SPECT images of the heart. The researchers said the technique may be useful to help assess interventions that inhibit apoptosis in myocardial infarction patients.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT076768

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel